Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to announce that the European Medicines Agency (EMA) has granted approval to commence a clinical trial for its highly-selective PARP1 inhibitor, DSB2455.

Duke Street Bio, a London based biotech focusing on the discovery of novel precision medicine-based cancer therapies, today strengthens its executive leadership team with the appointment of Jeff Thompson, PhD, MBA, as Head of Clinical Operations.

Duke Street Bio has strengthed its executive leadership team with the appointment of Dónal Landers, MB BCh BAO, MBA, DPM, FFPM as Chief Medical Officer.